Adaptive Biotechnologies (ADPT) Competitors

$12.83 -0.35 (-2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$13.56 +0.73 (+5.65%)

As of 04:38 PM Eastern

ADPT vs. NUVL, PCVX, KYMR, QGEN, and TGTX

Should you buy Adaptive Biotechnologies stock or one of its competitors? MarketBeat compares Adaptive Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adaptive Biotechnologies include Nuvalent (NUVL), Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Qiagen (QGEN), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

How does Adaptive Biotechnologies compare to Nuvalent?

Adaptive Biotechnologies (NASDAQ:ADPT) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Nuvalent had 7 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 15 mentions for Nuvalent and 8 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.35 beat Nuvalent's score of 0.16 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvalent has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Nuvalent	N/A	-40.11%	-35.43%

Adaptive Biotechnologies has higher revenue and earnings than Nuvalent. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	7.41	-$59.50M	-$0.33	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Adaptive Biotechnologies presently has a consensus price target of $19.57, indicating a potential upside of 52.54%. Nuvalent has a consensus price target of $137.25, indicating a potential upside of 34.16%. Given Adaptive Biotechnologies' higher possible upside, equities research analysts plainly believe Adaptive Biotechnologies is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

Adaptive Biotechnologies has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Summary

Adaptive Biotechnologies beats Nuvalent on 10 of the 15 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 64.15%. Adaptive Biotechnologies has a consensus target price of $19.57, indicating a potential upside of 52.54%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.99 beat Adaptive Biotechnologies' score of 0.35 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Vaxcyte's return on equity of -32.51% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Adaptive Biotechnologies has higher revenue and earnings than Vaxcyte. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Adaptive Biotechnologies	$276.98M	7.41	-$59.50M	-$0.33	N/A

Vaxcyte has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

Summary

Adaptive Biotechnologies beats Vaxcyte on 8 of the 13 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Kymera Therapeutics had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 11 mentions for Kymera Therapeutics and 8 mentions for Adaptive Biotechnologies. Kymera Therapeutics' average media sentiment score of 0.42 beat Adaptive Biotechnologies' score of 0.35 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kymera Therapeutics presently has a consensus target price of $118.10, indicating a potential upside of 43.65%. Adaptive Biotechnologies has a consensus target price of $19.57, indicating a potential upside of 52.54%. Given Adaptive Biotechnologies' higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Adaptive Biotechnologies has higher revenue and earnings than Kymera Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	172.47	-$311.35M	-$3.57	N/A
Adaptive Biotechnologies	$276.98M	7.41	-$59.50M	-$0.33	N/A

Adaptive Biotechnologies has a net margin of -16.82% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Kymera Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

Summary

Kymera Therapeutics beats Adaptive Biotechnologies on 9 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Qiagen?

Qiagen (NYSE:QGEN) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Qiagen has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.25	$424.88M	$1.91	17.28
Adaptive Biotechnologies	$276.98M	7.41	-$59.50M	-$0.33	N/A

In the previous week, Qiagen had 7 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 15 mentions for Qiagen and 8 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.35 beat Qiagen's score of 0.29 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has a net margin of 19.16% compared to Adaptive Biotechnologies' net margin of -16.82%. Qiagen's return on equity of 14.40% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Qiagen presently has a consensus target price of $46.38, indicating a potential upside of 40.53%. Adaptive Biotechnologies has a consensus target price of $19.57, indicating a potential upside of 52.54%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

70.0% of Qiagen shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Qiagen has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

Summary

Qiagen beats Adaptive Biotechnologies on 10 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to TG Therapeutics?

Adaptive Biotechnologies (NASDAQ:ADPT) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	7.41	-$59.50M	-$0.33	N/A
TG Therapeutics	$616.29M	9.81	$447.18M	$2.86	13.81

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than TG Therapeutics. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 4 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.79 beat Adaptive Biotechnologies' score of 0.35 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Adaptive Biotechnologies' net margin of -16.82%. TG Therapeutics' return on equity of 88.73% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
TG Therapeutics	65.95%	88.73%	43.44%

Adaptive Biotechnologies currently has a consensus target price of $19.57, indicating a potential upside of 52.54%. TG Therapeutics has a consensus target price of $52.50, indicating a potential upside of 32.91%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Adaptive Biotechnologies has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Summary

TG Therapeutics beats Adaptive Biotechnologies on 11 of the 17 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.05B	$3.32B	$6.22B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-38.88	18.05	20.38	25.28
Price / Sales	7.41	284.22	542.54	73.29
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	9.16	6.73	9.81	6.91
Net Income	-$59.50M	$24.11M	$3.56B	$333.88M
7 Day Performance	-7.10%	4.11%	0.43%	0.16%
1 Month Performance	-11.70%	-2.89%	-0.87%	1.90%
1 Year Performance	44.00%	69.06%	36.28%	32.84%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	3.2915 of 5 stars	$12.83 -2.7%	$19.57 +52.5%	+45.8%	$2.05B	$276.98M	N/A	790	Analyst Forecast
NUVL Nuvalent	2.8629 of 5 stars	$104.55 -0.7%	$137.25 +31.3%	+47.0%	$8.28B	N/A	N/A	40	Analyst Revision
PCVX Vaxcyte	2.9055 of 5 stars	$53.99 +1.8%	$86.00 +59.3%	+82.0%	$7.65B	N/A	N/A	160	Options Volume
KYMR Kymera Therapeutics	2.3614 of 5 stars	$84.10 -2.3%	$118.10 +40.4%	+184.0%	$7.08B	$39.21M	N/A	170
QGEN Qiagen	4.5567 of 5 stars	$32.63 -1.3%	$46.38 +42.1%	-23.3%	$6.81B	$2.09B	17.04	5,654	Dividend Increase Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. NUVL, PCVX, KYMR, QGEN, and TGTX

How does Adaptive Biotechnologies compare to Nuvalent?

Summary

How does Adaptive Biotechnologies compare to Vaxcyte?

Summary

How does Adaptive Biotechnologies compare to Kymera Therapeutics?

Summary

How does Adaptive Biotechnologies compare to Qiagen?

Summary

How does Adaptive Biotechnologies compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. NUVL, PCVX, KYMR, QGEN, and TGTX

How does Adaptive Biotechnologies compare to Nuvalent?

Does the media refer more to ADPT or NUVL?

Is ADPT or NUVL more profitable?

Which has better earnings & valuation, ADPT or NUVL?

Do insiders & institutionals believe in ADPT or NUVL?

Do analysts recommend ADPT or NUVL?

Which has more risk & volatility, ADPT or NUVL?

Summary

How does Adaptive Biotechnologies compare to Vaxcyte?

Do institutionals & insiders believe in PCVX or ADPT?

Do analysts prefer PCVX or ADPT?

Does the media prefer PCVX or ADPT?

Is PCVX or ADPT more profitable?

Which has preferable valuation and earnings, PCVX or ADPT?

Which has more volatility and risk, PCVX or ADPT?

Summary

How does Adaptive Biotechnologies compare to Kymera Therapeutics?

Does the media prefer KYMR or ADPT?

Do institutionals & insiders believe in KYMR or ADPT?

Do analysts prefer KYMR or ADPT?

Which has better valuation & earnings, KYMR or ADPT?

Is KYMR or ADPT more profitable?

Which has more volatility & risk, KYMR or ADPT?

Summary

How does Adaptive Biotechnologies compare to Qiagen?

Which has better valuation & earnings, QGEN or ADPT?

Does the media prefer QGEN or ADPT?

Is QGEN or ADPT more profitable?

Do analysts prefer QGEN or ADPT?

Do institutionals & insiders believe in QGEN or ADPT?

Which has more volatility & risk, QGEN or ADPT?

Summary

How does Adaptive Biotechnologies compare to TG Therapeutics?

Do institutionals and insiders believe in ADPT or TGTX?

Which has higher earnings & valuation, ADPT or TGTX?

Does the media refer more to ADPT or TGTX?

Is ADPT or TGTX more profitable?

Do analysts recommend ADPT or TGTX?

Which has more volatility & risk, ADPT or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools